147 related articles for article (PubMed ID: 34600405)
1. The role of surgery in the treatment of oligoprogression after systemic treatment for advanced non-small cell lung cancer.
Joosten PJM; de Langen AJ; van der Noort V; Monkhorst K; Klomp HM; Veenhof AAFA; Dickhoff C; Smit EF; Hartemink KJ
Lung Cancer; 2021 Nov; 161():141-151. PubMed ID: 34600405
[TBL] [Abstract][Full Text] [Related]
2. Local Therapy for Oligoprogressive Disease in Patients With Advanced Stage Non-small-cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutation.
Qiu B; Liang Y; Li Q; Liu G; Wang F; Chen Z; Liu M; Zhao M; Liu H
Clin Lung Cancer; 2017 Nov; 18(6):e369-e373. PubMed ID: 28465010
[TBL] [Abstract][Full Text] [Related]
3. Progression Patterns, Treatment, and Prognosis Beyond Resistance of Responders to Immunotherapy in Advanced Non-Small Cell Lung Cancer.
Xu Y; Li H; Fan Y
Front Oncol; 2021; 11():642883. PubMed ID: 33747966
[TBL] [Abstract][Full Text] [Related]
4. Stereotactic Body Radiation Therapy for Oligoprogressive and Oligorecurrent Non-Small-Cell Lung Cancer.
Ebadi M; Ladbury C; Liu J; Rock A; Onyshchenko M; Villaflor V; Villalona-Calero M; Salgia R; Massarelli E; Lee P; Williams T; Amini A
Clin Lung Cancer; 2023 Nov; 24(7):651-659. PubMed ID: 37714807
[TBL] [Abstract][Full Text] [Related]
5. Combing stereotactic body radiotherapy with checkpoint inhibitors after oligoprogression in advanced non-small cell lung cancer.
Wang Z; Wei L; Li J; Zhou H; Li S; Chen D; Yu Y; Zhao L; Zhu X; Song Y
Transl Lung Cancer Res; 2021 Dec; 10(12):4368-4379. PubMed ID: 35070747
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of local therapy for oligoprogressive disease after programmed cell death 1 blockade in advanced non-small cell lung cancer.
Kagawa Y; Furuta H; Uemura T; Watanabe N; Shimizu J; Horio Y; Kuroda H; Inaba Y; Kodaira T; Masago K; Fujita S; Niimi A; Hida T
Cancer Sci; 2020 Dec; 111(12):4442-4452. PubMed ID: 32770608
[TBL] [Abstract][Full Text] [Related]
7. Treatment strategies based on different oligoprogressive patterns after immunotherapy failure in metastatic NSCLC.
Xuzhang W; Huang H; Yu Y; Shen L; Li Z; Lu S
Ther Adv Med Oncol; 2023; 15():17588359231156387. PubMed ID: 36895853
[TBL] [Abstract][Full Text] [Related]
8. Radiotherapy with continued EGFR-TKIs for oligoprogressive disease in EGFR-mutated non-small cell lung cancer: A real-world study.
Hu C; Wu S; Deng R; Wu Y; Pan Y; Shu L; Wu F
Cancer Med; 2023 Jan; 12(1):266-273. PubMed ID: 35666038
[TBL] [Abstract][Full Text] [Related]
9. Definitive radiotherapy for extracranial oligoprogressive metastatic renal cell carcinoma as a strategy to defer systemic therapy escalation.
De B; Venkatesan AM; Msaouel P; Ghia AJ; Li J; Yeboa DN; Nguyen QN; Bishop AJ; Jonasch E; Shah AY; Campbell MT; Wang J; Zurita-Saavedra AJ; Karam JA; Wood CG; Matin SF; Tannir NM; Tang C
BJU Int; 2022 May; 129(5):610-620. PubMed ID: 34228889
[TBL] [Abstract][Full Text] [Related]
10. Bombarding Oligoprogression: Oncologic Outcomes After Radiation to Patients With Oligoprogressive Non-Small Cell Lung Cancer on Maintenance Systemic Therapy.
Chou B; Lee JH; Saetern L; Venkatesulu BP; Welsh JS; Harkenrider MM
Am J Clin Oncol; 2024 Apr; 47(4):155-160. PubMed ID: 38193499
[TBL] [Abstract][Full Text] [Related]
11. Surgery for thoracic oligoprogression in metastatic renal cell cancer in the era of new systemic therapies.
Le UT; Passlick B; Schmid S
J Thorac Dis; 2023 Mar; 15(3):1133-1141. PubMed ID: 37065601
[TBL] [Abstract][Full Text] [Related]
12. Multisite stereotactic body radiotherapy for metastatic non-small-cell lung cancer: Delaying the need to start or change systemic therapy?
Merino Lara T; Helou J; Poon I; Sahgal A; Chung HT; Chu W; Soliman H; Ung Y; Verma S; Cheema P; Cheng S; Khanna S; Erler D; Zhang L; Cheung P
Lung Cancer; 2018 Oct; 124():219-226. PubMed ID: 30268464
[TBL] [Abstract][Full Text] [Related]
13. Microwave ablation as local consolidative therapy for patients with extracranial oligometastatic EGFR-mutant non-small cell lung cancer without progression after first-line EGFR-TKIs treatment.
Ni Y; Ye X; Yang X; Huang G; Li W; Wang J; Han X; Wei Z; Meng M
J Cancer Res Clin Oncol; 2020 Jan; 146(1):197-203. PubMed ID: 31599340
[TBL] [Abstract][Full Text] [Related]
14. [Value of surgery for stage IIIa non-small cell lung cancer].
Liu H; Wang M; Hu K; Xu Y; Ma M; Zhong W; Zhao J; Li L; Wang H
Zhongguo Fei Ai Za Zhi; 2013 Dec; 16(12):639-45. PubMed ID: 24345488
[TBL] [Abstract][Full Text] [Related]
15. Local Thermal Ablation with Continuous EGFR Tyrosine Kinase Inhibitors for EGFR-Mutant Non-small Cell Lung Cancers that Developed Extra-Central Nervous System (CNS) Oligoprogressive Disease.
Ni Y; Liu B; Ye X; Fan W; Bi J; Yang X; Huang G; Li W; Wang J; Han X; Wei Z; Meng M
Cardiovasc Intervent Radiol; 2019 May; 42(5):693-699. PubMed ID: 30701290
[TBL] [Abstract][Full Text] [Related]
16. Retrospective Review of Outcomes After Radiation Therapy for Oligoprogressive Disease on Immune Checkpoint Blockade.
Mahmood U; Huynh MA; Killoran JH; Qian JM; Bent EH; Aizer AA; Mak RH; Mamon HJ; Balboni TA; Gunasti L; Ott PA; Awad MM; Schoenfeld JD
Int J Radiat Oncol Biol Phys; 2022 Nov; 114(4):666-675. PubMed ID: 35643252
[TBL] [Abstract][Full Text] [Related]
17. Stereotactic body radiotherapy prolongs the progression-free survival and delays the change of systemic therapy regimen in patients with lung oligoprogressive metastatic colorectal cancer.
Li S; Dong D; Geng J; Zhu X; Shi C; Zhang Y; Wang H; Zhou S; Wu H; Cai Y; Li Y; Wang W
Asia Pac J Clin Oncol; 2022 Apr; 18(2):e64-e72. PubMed ID: 33629479
[TBL] [Abstract][Full Text] [Related]
18. The Role of Radiotherapy in Epidermal Growth Factor Receptor Mutation-positive Patients with Oligoprogression: A Matched-cohort Analysis.
Chan OSH; Lee VHF; Mok TSK; Mo F; Chang ATY; Yeung RMW
Clin Oncol (R Coll Radiol); 2017 Sep; 29(9):568-575. PubMed ID: 28499791
[TBL] [Abstract][Full Text] [Related]
19. Durable disease control with local treatment for oligoprogression of metastatic solid tumors treated with immune checkpoint blockade.
Sindhu KK; Leiter A; Moshier E; Lin JY; Carroll E; Brooks D; Shimol JB; Eisenberg E; Gallagher EJ; Stock RG; Galsky MD; Buckstein M
Cancer Treat Res Commun; 2020; 25():100216. PubMed ID: 33049542
[TBL] [Abstract][Full Text] [Related]
20. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
